BIOMAT Database Logo BIOMAT Database Logo

A preliminary evaluation of nelfinavir mesylate, an inhibitor of human immunodeficiency virus (HIV)-1 protease, to treat HIV infection. 1998

M Markowitz, and M Conant, and A Hurley, and R Schluger, and M Duran, and J Peterkin, and S Chapman, and A Patick, and A Hendricks, and G J Yuen, and W Hoskins, and N Clendeninn, and D D Ho
Aaron Diamond AIDS Research Center, Rockefeller University, New York, New York 10016, USA.

A phase I/II dose-ranging open-label 28-day monotherapy study of the safety, pharmacokinetics, and antiviral activity of nelfinavir mesylate (Viracept), an inhibitor of human immunodeficiency virus (HIV)-1 protease, was done in 65 HIV-1-infected subjects. After 28 days, 54 responding subjects entered an open-label extension that allowed for the addition of nucleoside inhibitors of reverse transcriptase and dose escalation to maintain durability. The drug was well-tolerated and demonstrated robust antiviral activity, with demonstrable superiority of the 750 mg and 1000 mg three times daily regimens. Thirty subjects who continued to receive therapy at 12 months attained a persistent 1.6 log10 reduction in HIV RNA, accompanied by a mean increase in CD4 cells of 180-200/mm3. Studies of viral genotype and phenotype after virus rebound revealed that the initial active site mutation allowing for nelfinavir resistance is mediated by a unique amino acid substitution in the HIV-1 protease D30N, which does not confer in vitro phenotypic cross-resistance to the currently available protease inhibitors.

UI MeSH Term Description Entries
D008297 Male Males
D004341 Drug Evaluation Any process by which toxicity, metabolism, absorption, elimination, preferred route of administration, safe dosage range, etc., for a drug or group of drugs is determined through clinical assessment in humans or veterinary animals. Evaluation Studies, Drug,Drug Evaluation Studies,Drug Evaluation Study,Drug Evaluations,Evaluation Study, Drug,Evaluation, Drug,Evaluations, Drug,Studies, Drug Evaluation,Study, Drug Evaluation
D004352 Drug Resistance, Microbial The ability of microorganisms, especially bacteria, to resist or to become tolerant to chemotherapeutic agents, antimicrobial agents, or antibiotics. This resistance may be acquired through gene mutation or foreign DNA in transmissible plasmids (R FACTORS). Antibiotic Resistance,Antibiotic Resistance, Microbial,Antimicrobial Resistance, Drug,Antimicrobial Drug Resistance,Antimicrobial Drug Resistances,Antimicrobial Resistances, Drug,Drug Antimicrobial Resistance,Drug Antimicrobial Resistances,Drug Resistances, Microbial,Resistance, Antibiotic,Resistance, Drug Antimicrobial,Resistances, Drug Antimicrobial
D005260 Female Females
D005500 Follow-Up Studies Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease. Followup Studies,Follow Up Studies,Follow-Up Study,Followup Study,Studies, Follow-Up,Studies, Followup,Study, Follow-Up,Study, Followup
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D012367 RNA, Viral Ribonucleic acid that makes up the genetic material of viruses. Viral RNA
D015497 HIV-1 The type species of LENTIVIRUS and the etiologic agent of AIDS. It is characterized by its cytopathic effect and affinity for the T4-lymphocyte. Human immunodeficiency virus 1,HIV-I,Human Immunodeficiency Virus Type 1,Immunodeficiency Virus Type 1, Human
D015658 HIV Infections Includes the spectrum of human immunodeficiency virus infections that range from asymptomatic seropositivity, thru AIDS-related complex (ARC), to acquired immunodeficiency syndrome (AIDS). HTLV-III Infections,HTLV-III-LAV Infections,T-Lymphotropic Virus Type III Infections, Human,HIV Coinfection,Coinfection, HIV,Coinfections, HIV,HIV Coinfections,HIV Infection,HTLV III Infections,HTLV III LAV Infections,HTLV-III Infection,HTLV-III-LAV Infection,Infection, HIV,Infection, HTLV-III,Infection, HTLV-III-LAV,Infections, HIV,Infections, HTLV-III,Infections, HTLV-III-LAV,T Lymphotropic Virus Type III Infections, Human

Related Publications

M Markowitz, and M Conant, and A Hurley, and R Schluger, and M Duran, and J Peterkin, and S Chapman, and A Patick, and A Hendricks, and G J Yuen, and W Hoskins, and N Clendeninn, and D D Ho
Treatment of human immunodeficiency virus 1-infected infants and children with the protease inhibitor nelfinavir mesylate.
May 1999, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America,
M Markowitz, and M Conant, and A Hurley, and R Schluger, and M Duran, and J Peterkin, and S Chapman, and A Patick, and A Hendricks, and G J Yuen, and W Hoskins, and N Clendeninn, and D D Ho
Activities of the human immunodeficiency virus type 1 (HIV-1) protease inhibitor nelfinavir mesylate in combination with reverse transcriptase and protease inhibitors against acute HIV-1 infection in vitro.
October 1997, Antimicrobial agents and chemotherapy,
M Markowitz, and M Conant, and A Hurley, and R Schluger, and M Duran, and J Peterkin, and S Chapman, and A Patick, and A Hendricks, and G J Yuen, and W Hoskins, and N Clendeninn, and D D Ho
Nelfinavir mesylate: a protease inhibitor.
March 1999, The Annals of pharmacotherapy,
M Markowitz, and M Conant, and A Hurley, and R Schluger, and M Duran, and J Peterkin, and S Chapman, and A Patick, and A Hendricks, and G J Yuen, and W Hoskins, and N Clendeninn, and D D Ho
A preliminary study of ritonavir, an inhibitor of HIV-1 protease, to treat HIV-1 infection.
December 1995, The New England journal of medicine,
M Markowitz, and M Conant, and A Hurley, and R Schluger, and M Duran, and J Peterkin, and S Chapman, and A Patick, and A Hendricks, and G J Yuen, and W Hoskins, and N Clendeninn, and D D Ho
Viracept (nelfinavir mesylate, AG1343): a potent, orally bioavailable inhibitor of HIV-1 protease.
November 1997, Journal of medicinal chemistry,
M Markowitz, and M Conant, and A Hurley, and R Schluger, and M Duran, and J Peterkin, and S Chapman, and A Patick, and A Hendricks, and G J Yuen, and W Hoskins, and N Clendeninn, and D D Ho
A Concise Formal Synthesis of the Potent HIV Protease Inhibitor Nelfinavir Mesylate.
November 1997, The Journal of organic chemistry,
M Markowitz, and M Conant, and A Hurley, and R Schluger, and M Duran, and J Peterkin, and S Chapman, and A Patick, and A Hendricks, and G J Yuen, and W Hoskins, and N Clendeninn, and D D Ho
Characterization of the selectivity and mechanism of human cytochrome P450 inhibition by the human immunodeficiency virus-protease inhibitor nelfinavir mesylate.
July 1998, Drug metabolism and disposition: the biological fate of chemicals,
M Markowitz, and M Conant, and A Hurley, and R Schluger, and M Duran, and J Peterkin, and S Chapman, and A Patick, and A Hendricks, and G J Yuen, and W Hoskins, and N Clendeninn, and D D Ho
Generation and characterization of a human immunodeficiency virus type 1 (HIV-1) mutant resistant to an HIV-1 protease inhibitor.
January 1994, Journal of virology,
M Markowitz, and M Conant, and A Hurley, and R Schluger, and M Duran, and J Peterkin, and S Chapman, and A Patick, and A Hendricks, and G J Yuen, and W Hoskins, and N Clendeninn, and D D Ho
Preliminary evaluation of human immunodeficiency virus type 1 (HIV-1) immunogen in children with HIV-1 infection.
September 1999, The Journal of infectious diseases,
M Markowitz, and M Conant, and A Hurley, and R Schluger, and M Duran, and J Peterkin, and S Chapman, and A Patick, and A Hendricks, and G J Yuen, and W Hoskins, and N Clendeninn, and D D Ho
Atazanavir: a new protease inhibitor to treat HIV infection.
July 2004, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists,
Copied contents to your clipboard!